Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack drug targets tiny vessels, not blockages

NCT ID NCT05198791

Disease control Sponsor: NHS National Waiting Times Centre Board Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests whether eplerenone, a drug used for high blood pressure and heart failure, can help people who have had a heart attack or heart injury but no blocked arteries. Many of these patients have damage to tiny blood vessels in the heart. The study will involve 400 adults in Scotland. Participants with small vessel problems will either get eplerenone or usual care for six months. The main goal is to see if the drug reduces heart injury markers and improves heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Eplerenone (a tablet that reduces blood vessel injury, used for high blood pressure and heart failure)
What this could lead to
If it works, this could point toward a treatment for heart damage caused by small vessel problems after a heart attack.
What could go wrong
This is an early phase 2 trial with only 400 participants, so results may not apply to everyone. The drug may not reduce heart injury or improve outcomes as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Acute myocardial infarction or myocardial injury and no obstructive coronary arteries. * Cardiovascular risk factor (≥1): age \>70 years, atrial fibrillation, diabetes, current smoker, eGFR 30 - 60 mL/ minute/1.73 m2, prior MI, treated hypertension or COVID-19 (confirmed or suspected) * Coronary angiography. Exclusion Criteria (trial): * Obstructive coronary artery disease * Left ventricular ejection fraction ≤40% with evidence of heart failure, following myocardial infarction. * Estimated glomerular filtration rate \<30 mL/ minute/1.73 m2 * Severe liver impairment * Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions defined in the eligibility criteria and use highly effective contraception as defined in Appendix 2 for the duration of the study treatment and 30 days after last dose of study drug. * Patients taking one of the following medicines : * Pre-existing treatment with an MRA : * Anti-fungal drugs (ketoconazole or itraconazole). * Antiviral medication (nelfinavir or ritonavir). * Antibiotics (clarithromycin or telithromycin). * Nefazodone used to treat depression. * The combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB)) together. Exclusion Criteria (registry): * Contra-indication to cardiovascular magnetic resonance imaging e.g. severe claustrophobia, metallic foreign body. * Contra-indication to intravenous adenosine, i.e. severe asthma; long QT syndrome; second- or third-degree atrio-ventricular block and sick sinus syndrome. * Lack of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction with nonobstructive coronary arteries are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction MINOCA myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction with nonobstructive coronary arteries Myocardial infarction, acute Myocardial injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Golden Jubilee National Hospital

    RECRUITING

    Glasgow, United Kingdom

  • University Hospital Hairmyres

    RECRUITING

    East Kilbride, Lanarkshire, G75 8RG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.